Development Of An Extended Release Oral Formulation Of Milrinone For Patients With Advanced Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$467,083.00
Summary
Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with indu ....Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with industry as a means to clinical translation.Read moreRead less
Developing A Safe Vaccine Against Group A Streptococci
Funder
National Health and Medical Research Council
Funding Amount
$768,530.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Sanofi Pasteur) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
A Non-invasive Fluid Status Monitoring Device For Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$360,715.00
Summary
Both acute decompensated heart failure (ADHF) and chronic kidney disease (CKD) are characterised by fluid overload. A device to detect this fluid overload in patients at an early stage has the potential to reduce the need for hospitalisation and initiate more timely and aggressive intervention. A prototype device has already been developed and our aim is to further improve on this device and advance to a commercial product.
Development Of A High Acuity, Diamond Retinal Prosthesis
Funder
National Health and Medical Research Council
Funding Amount
$1,010,214.00
Summary
Over recent years our team has developed a retinal implant to restore sight to people with certain types of blindness. With 256 independently controllable electrodes this device is among the most sophisticated in the world. We aim to conduct experiments to demonstrate that our device can provide improved better visual acuity than the world leaders with a view to developing a competitive commercial medical technology.
Compound Culture Media To Improve Human IVF Pregnancies
Funder
National Health and Medical Research Council
Funding Amount
$254,340.00
Summary
In Australia 1 in 6 couples require IVF to conceive. Although pregnancy rates have improved over the last 10 years the live birth rate in Australia per cycle is only 17%. This project will assess a new method for the culture of embryos for the ability to maintain embryo vitality and produce healthy babies.
Development Of A Novel Microfluidic Device To Treat Male Infertility
Funder
National Health and Medical Research Council
Funding Amount
$508,397.00
Summary
This research aims to develop a novel technology for the separation of high quality sperm. It is envisaged this will replace existing technology to improve the reproductive outcomes of both humans, as well as animals.
From The Synchrotron To The Clinic: Translation Of A Novel Functional Lung Imaging Technology
Funder
National Health and Medical Research Council
Funding Amount
$891,834.00
Summary
Our team has recently developed a synchrotron technology with a startling capacity for dynamic functional imaging that can act as a sensitive regional indicator of lung disease. We will demonstrate that this technology can be translated from the synchrotron to the lab and eventually the clinic. We will provide proof of this concept by the application of this technology to emphysema, asthma, lung cancer, cystic fibrosis lung disease and neonatal resuscitation.